China Jolts U.S. Markets; Trump Chip Policy Under Scrutiny; Silver Market Volatility Rises
Nuformix plc
LSE:NFX
GBp 0.225
-0.005 (-2.17%)
EOD - 2026-01-28
Market cap
4.75M
Enterprise value
3.66M
Volume
43.21M
PE
-
50 Day MA
0.27
200 Day MA
0.18
EPS
-0.0
Currency
GBp
Number of Shares
2,109.75M
Learn the Markets
Nuformix plc Price Highlights 🏷️
1 Day
-2.17%
1 Week
-23.73%
1 Month
-10%
6 Months
188.46%
1 Year
55.17%
Nuformix plc Price Chart 📈
Buy and Sell Nuformix plc 🛒
EToro |
Live Trading |
Buy & Sell
|
Trading 212 |
Live Trading |
Buy & Sell
|
ShareScope |
Paper Trading |
Learn How
|
Investor Returns 👀
£
1 Week
£0
-23.73%
1 Month
£0
-10%
1 Year
+£0
+55.17%
Jigglypop Analysis For Nuformix plc 🤓
2026-01-15
Nuformix trades at 0.2736p, midway in its 52-week 0.05 to 0.555p range, and below the 50-day average but above the 200-day. That positioning, plus an 11x range, signals momentum and volatility rather than deep value. A £5.8m micro-cap, it recently raised £0.23m at 0.2p, confirming capital needs and dilution. Near-term sentiment hinges on FDA feedback regarding NXP002 orphan status after EMA approval, alongside progress in NXP001 and NXP004 partnering. With the shares 51% below the high yet over 4x the low, risk-reward skews to binary clinical and deal outcomes. Our take: this is a speculative play, not a value play, with catalysts ahead in the near term but execution and funding risk in view. Position sizes should reflect that volatility.
About Nuformix plc 👋
Nuformix plc, together with its subsidiary Nuformix Technologies Limited, focuses on pharmaceutical R&D in the UK, repurposing drugs to treat fibrosis and cancer. Its pipeline includes NXP001, now in Phase 1 for oncology supportive care; NXP002, at the preclinical stage for idiopathic pulmonary fibrosis; and NXP004, a novel form of olaparib, currently in IP creation for oncology. The company also has an option agreement with Oxilio Ltd. relating to NXP001 for oncology indications. Founded in 2008, Nuformix plc is based in London, United Kingdom.
Nuformix plc Price Range 🎯
Low
0.06
0.06
Last 52 Weeks
High
0.555
0.555
All-time high
GBp 0.247
All-time low
GBp 0.2145
Ownership Breakdown 🤝
Nuformix plc Consensus.
💰
Brokers Consensus
None
Nuformix plc Directors.
Dr. Daniel John Gooding
Dr. Joanne M. Holland
Shaun Zulafqar
Trending Tickers View all UK Stocks →
Frequent Asked Questions 💬
LSE:NFX has around 3 people working for the Company.
LSE:NFX belongs to the Healthcare Sector.
The 200 day MA value for Nuformix plc is 0.18.
The 50 day MA value for Nuformix plc is 0.27.
The ATH price for Nuformix plc is 0.247.
The ATL price for Nuformix plc is 0.2145.
News Bites 🗞️
🚨
Company Update
Nuformix raised approximately GBP228,081 via an underwritten open offer at 0.2 pence per share. Valid acceptances exceeded the 114.0 million shares available; 114.0 million shares will be issued. Excess applications will be scaled back pro rata. Dealings in the new shares are expected to commence in London on Thursday.
🚨
Company Update
FDA requested further clarification on one element of Nuformix’s orphan drug designation application for tranilast in idiopathic pulmonary fibrosis. Nuformix plans to respond using existing data. Following review, FDA may issue designation confirmation, seek additional information, or deny the application. The company said it continues discussions with potential future licensing partners and will provide further updates.
🚨
Company Update
Nuformix submitted a US FDA orphan drug designation application for its NXP002 programme in idiopathic pulmonary fibrosis. The company said the EMA has granted orphan drug designation for NXP002 in the EU. It is continuing discussions with potential future licensing partners and plans further updates.
🚨
Company Update
Nuformix said its lead programme NXP002 received European Medicines Agency orphan drug designation for idiopathic pulmonary fibrosis, applying to tranilast, the active compound in NXP002 for inhaled delivery. Orphan designation provides incentives including market exclusivity, reduced fees and regulatory support. The company plans to seek FDA orphan designation and is in discussions with potential licensing partners.
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial, investment, or trading advice. Cryptocurrency and stock investments involve risk, and you should conduct your own research or consult with a qualified financial advisor before making any investment decisions. Past performance does not guarantee future results.
© Jigglypop. All rights reserved.